Literature DB >> 33766013

Considerations for applying bioethics norms to a biopharmaceutical industry setting.

Luann E Van Campen1,2, Tatjana Poplazarova3, Donald G Therasse4, Michael Turik4,5.   

Abstract

BACKGROUND: The biopharmaceutical industry operates at the intersection of life sciences, clinical research, clinical care, public health, and business, which presents distinct operational and ethical challenges. This setting merits focused bioethics consideration to complement legal compliance and business ethics efforts. However, bioethics as applied to a biopharmaceutical industry setting often is construed either too broadly or too narrowly with little examination of its proper scope. MAIN TEXT: Any institution with a scientific or healthcare mission should engage bioethics norms to navigate ethical issues that arise from the conduct of biomedical research, delivery of clinical care, or implementation of public health programs. It is reasonable to assume that while bioethics norms must remain constant, their application will vary depending on the characteristics of a given setting. Context "specification" substantively refines ethics norms for a particular discipline or setting and is an expected, needed and progressive ethical activity. In order for this activity to be meaningful, the scope for bioethics application and the relevant contextual factors of the setting need to be delineated and appreciated. This paper defines biopharmaceutical bioethics as: the application of bioethics norms (concepts, principles, and rules) to the research, development, supply, commercialization, and clinical use of biopharmaceutical healthcare products. It provides commentary on this definition, and presents five contextual factors that need to be considered when applying bioethics norms to a biopharmaceutical industry setting: (1) dual missions; (2) timely and pragmatic guidance; (3) resource stewardship; (4) multiple stakeholders; and (5) operational complexity.
CONCLUSION: Understanding the scope of the biopharmaceutical enterprise and contextual factors of a biopharmaceutical industry setting is foundational for the application of bioethics norms. Establishing a common language and approach for biopharmaceutical bioethics will facilitate breadth and depth of discussion and subsequent implementation to benefit patients, the healthcare system and society.

Entities:  

Keywords:  Bioethics norms; Biopharmaceutical industry; Context; Definition; Setting; Specification

Year:  2021        PMID: 33766013      PMCID: PMC7992125          DOI: 10.1186/s12910-021-00600-y

Source DB:  PubMed          Journal:  BMC Med Ethics        ISSN: 1472-6939            Impact factor:   2.652


  33 in total

1.  Businesses are buying the ethics they want.

Authors:  Raymond DeVries
Journal:  Washington Post       Date:  2004-02-08

2.  Ethical decision-making in bioscience firms.

Authors:  David Finegold; Allison Moser
Journal:  Nat Biotechnol       Date:  2006-03       Impact factor: 54.908

3.  Innovation and the Pharmaceutical Industry: Critical Reflections on the Virtues of Profit, H.T. Engelhardt, Jr. and J.R. Garrett (eds.) (Salem: M & M Scrivener Press, 2008).

Authors:  Erica K Rangel
Journal:  HEC Forum       Date:  2008-12

4.  Practical, legal, and ethical issues in expanded access to investigational drugs.

Authors:  Jonathan J Darrow; Ameet Sarpatwari; Jerry Avorn; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2015-01-15       Impact factor: 91.245

5.  Pharmaceutical R&D performance by firm size: approval success rates and economic returns.

Authors:  Joseph A DiMasi
Journal:  Am J Ther       Date:  2014 Jan-Feb       Impact factor: 2.688

6.  Clinical development success rates for investigational drugs.

Authors:  Michael Hay; David W Thomas; John L Craighead; Celia Economides; Jesse Rosenthal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

7.  Prescription Requirements and Patient Autonomy: Considering an Over-the-Counter Default.

Authors:  Madison Kilbride; Steven Joffe; Holly Fernandez Lynch
Journal:  Hastings Cent Rep       Date:  2020-11       Impact factor: 2.683

8.  Development, implementation and critique of a bioethics framework for pharmaceutical sponsors of human biomedical research.

Authors:  Luann E Van Campen; Donald G Therasse; Mitchell Klopfenstein; Robert J Levine
Journal:  Curr Med Res Opin       Date:  2015-10-15       Impact factor: 2.580

9.  Eli Lilly and Company's bioethics framework for human biomedical research.

Authors:  Luann E Van Campen; Donald G Therasse; Mitchell Klopfenstein; Robert J Levine
Journal:  Curr Med Res Opin       Date:  2015-10-13       Impact factor: 2.580

10.  Ethical decision-making in biopharmaceutical research and development: applying values using the TRIP & TIPP model.

Authors:  Tatjana Poplazarova; Claar van der Zee; Thomas Breuer
Journal:  Hum Vaccin Immunother       Date:  2020-01-15       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.